scholarly journals Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer

2012 ◽  
Vol 3 (3) ◽  
pp. 530-534 ◽  
Author(s):  
DANIEL T. REIN ◽  
ANNE KATHRIN VOLKMER ◽  
JENS VOLKMER ◽  
INES M. BEYER ◽  
WOLFGANG JANNI ◽  
...  
2021 ◽  
Vol 11 (10) ◽  
Author(s):  
Simone Pisano ◽  
Stefania Lenna ◽  
Gareth D. Healey ◽  
Fereshteh Izardi ◽  
Lucille Meeks ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Ying Zhang ◽  
Li Luo ◽  
Xueling Zheng ◽  
Tinghe Yu

A nude mouse received subcutaneous injection of human ovarian cancer cells HO-8910PM to form a tumor, and then the tumor fragment was surgically transplanted to the ovary of a recipient mouse to establish an orthotopic cancer model. Tumors occurred in 100% of animals. A mouse displayed an ovarian mass, ascites, intraperitoneal spread, and lung metastasis at natural death. The mean survival time was34.1±17.2days, with median survival time of 28.5 days. The findings indicated that the present mouse model can reflect the biological behavior of advanced human ovarian cancers. This in vivo model can be used to explore therapeutic means against chemoresistance and metastasis, and an effective treatment would prolong the survival time.


BMC Cancer ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Luiz Gustavo A Chuffa ◽  
Beatriz A Fioruci-Fontanelli ◽  
Leonardo O Mendes ◽  
Fábio R Ferreira Seiva ◽  
Marcelo Martinez ◽  
...  

1994 ◽  
Vol 58 (8) ◽  
pp. 972-974 ◽  
Author(s):  
Anne Delvaux ◽  
Vincent Donckier ◽  
Catherine Bruyns ◽  
Sandrine Florquin ◽  
Catherine Gérard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document